Nestlé's Microbiome Interest Deepens With Enterome JV

 
• By Catherine Longworth
  
Generate a summary of this article
Listen to this article
Beta

Nestlé Health Science has invested $23m in a joint venture it is setting up with French microbiome company Enterome. Microbiome Diagnostics Partners (MDP) will be focused on developing microbiome-based diagnostics for the assessment and management of irritable bowel disorder and liver diseases.

Handshake of businessmen

French microbiome company Enterome is teaming up with Swiss nutritionals giant Nestlé Health Science to form a joint venture focused on developing microbiome-based diagnostics. Nestlé will invest €20m ($23m) in return for a 50% stake in Microbiome Diagnostics Partners (MDP). In addition, it will make further payments to MDP if it achieves certain clinical and commercial milestones. Enterome will contribute to the JV its current microbiome diagnostic programs and intellectual property derived from its microbiome-based platforms.

The main focus of the joint venture will be to accelerate commercialization of Enterome's diagnostic platforms which include IBD110, a...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Deals

Investor Eye: Intuitive Surgical Hops, Skips, And Jumps Into VC

 
• By Barnaby Pickering

When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.

test carousel-Medtech

 
• By Saba Afreen

test carousel-Medtech

MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain

 
• By Nabil

Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.

Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 
• By Natasha Barrow

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

More from Business

test carousel-Medtech

 
• By Saba Afreen

test carousel-Medtech

test carousel

 
• By Saba Afreen and Krsihna

test carousel-HBW

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.